Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17956339 | 0.85 | CYP19A1 (0.51) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL9935276 | 0.84 | CYP19A1 (0.54) | CYP19A1PLAUHTR1ASIGMAR1OPRM1 | |
| SCHEMBL9567953 | 0.81 | GBA1 (0.55) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL5712654 | 0.81 | PLAU (0.52) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL9139949 | 0.81 | HTR1A (0.53) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL29992701 | 0.81 | PLAU (0.52) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL6428907 | 0.80 | CYP19A1 (0.54) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL6427588 | 0.80 | CYP19A1 (0.54) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL6427595 | 0.80 | CYP19A1 (0.54) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL23368972 | 0.78 | GRIN2B (0.55) | CYP19A1HTR1ASIGMAR1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039500-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | CRHR1, CRHR2, CRH | CYP19A1 403/4885GBA1 4278/4885PLAU 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.